Welcome to the WCN 2021 Interactive Program
The congress will officially run on Central European Time (CET) - Rome Time
To convert the congress times to your local time Click Here
Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A/Discussion at the end
The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Virtual Platform
- Matthew J. Thurtell (United States of America)
- Marc J. Dinkin (United States of America)
- Marianne De Visser (Netherlands)
- Bo Norrving (Sweden)
- Claudia Trenkwalder (Germany)
- Masud Husain (United Kingdom)
- Massimo Filippi (Italy)
- Carlo Pozzilli (Italy)
- Antonio Uccelli (Italy)
This symposium aims to:
- Spread the knowledge of a pathophysiologic mechanism that not many clinicians know properly, but that is proven to be one of the trigger causes of NMOSD (Neuromyelitis Optica Spectrum Disorder) and gMG (generalized Myasthenia Gravis), two immune mediated rare neurological diseases.
- Present data for eculizumab on both diseases and highlight innovation in therapeutic environment thanks to the discussion with experts.
- Bart Van Wijmeersch (Belgium)
- Massimo Filippi (Italy)
Join this symposium to learn about the key data that have led to the EMA approval of the subcutaneous use of natalizumab, gain practical insights into using this new route of administration in clinical practice, and keep up-to-date on the latest evidence to maximize the safe, effective use of natalizumab.
The faculty will provide three presentations on the latest advances in treatment with natalizumab followed by a live question-and-answer session. During the session, the online audience can ask questions to the expert panel.
- Cristina Tassorelli (Italy)
During this symposium, we will consider the myriad social determinants of health in general and – focusing on migraine specifically – critique the current state of diversity in clinical studies. We will also review what the latest data tell us about the efficacy and tolerability of monoclonal antibodies targeting the calcitonin gene-related peptide pathway (CGRP mAbs) for migraine prevention across diverse patient subgroups, including different ethnicities, migraine characteristics and comorbidities.
We hope you will join us as we attempt to address this important question: are we making progress towards a more inclusive, diverse, and equitable global migraine landscape?
- Carlayne E. Jackson (United States of America)